In its Q4 2025 earnings call, SL Green Realty projected strong fundamentals for Manhattan's office market, citing robust leasing and AI-driven demand. Management reiterated ambitious 2026 financing and asset sale targets while reporting quarterly results that beat expectations.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Despite a persistently muted demand environment, Sherwin-Williams reported robust fourth-quarter earnings, driven by cost discipline and strategic acquisitions. The paint giant forecasts low-to-mid single-digit sales growth for 2026 while reinstating employee benefits, signaling cautious optimism amid ongoing economic headwinds.
Investment bank Macquarie has lowered its price target for Chinese EV maker XPeng, pointing to reduced government subsidies and a complex path to profitability as the company expands its model lineup.
Brokerage firm CLSA initiates coverage on Atour Lifestyle Holdings with an 'Outperform' rating and a $49 price target, highlighting its unique brand ecosystem and asset-light model as key differentiators in a competitive market.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.
Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.
Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.
With key self-assessment deadlines approaching, property investors must navigate a changed landscape of tax reliefs and allowable expenses to minimise their liabilities. Experts urge early preparation to avoid costly surprises.
With the annual self-assessment deadline a perennial source of stress for freelancers and sole traders, this guide breaks down the essentials of income tax and National Insurance. The landscape is set for a significant shift with the incoming Making Tax Digital regime, making this a crucial year to get to grips with the current rules.
A quirk in the UK tax system means those earning between £100,000 and £125,140 face an effective 60% marginal tax rate, while also losing crucial childcare benefits. We examine the growing trap and the financial planning strategies to navigate it.
Chinese regulators have conditionally approved leading AI startup DeepSeek to purchase Nvidia's advanced H200 artificial intelligence chips, sources tell Reuters, as Beijing navigates competing pressures to advance its tech sector while managing geopolitical tensions.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
The long-standing pillar of UK e-commerce—free and unlimited returns—is facing a fundamental overhaul as soaring costs and changing consumer habits force retailers to adopt more targeted and sustainable policies.
ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.
Robert Half International reports a pivotal return to sequential revenue growth in Q4 2025, signaling a potential turning point after a prolonged slump. However, the staffing giant continues to grapple with significant year-over-year declines, highlighting an uneven recovery path for the broader professional labor market.
Despite facing what its CEO called "highly variable" housing demand in 2025, PulteGroup reported another year of robust revenue and earnings, driven by its diversified buyer mix and strength in the active-adult segment. While Q4 profitability softened, the homebuilder is betting on strategic land investments and a resilient spring selling season to fuel its 2026 outlook.
